TherapeuticsMD Company Profile (NYSEMKT:TXMD)

About TherapeuticsMD (NYSEMKT:TXMD)

TherapeuticsMD logoTherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $1.23 billion
  • Outstanding Shares: 204,027,000
Average Prices:
  • 50 Day Moving Avg: $5.48
  • 200 Day Moving Avg: $5.54
  • 52 Week Range: $3.50 - $8.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -23.12
  • P/E Growth: -1.00
Sales & Book Value:
  • Annual Revenue: $18.26 million
  • Price / Sales: 67.15
  • Book Value: $0.46 per share
  • Price / Book: 13.07
Profitability:
  • EBIDTA: ($88,990,000.00)
  • Net Margins: -462.94%
  • Return on Equity: -77.41%
  • Return on Assets: -68.24%
Misc:
  • Average Volume: 2.65 million shs.
  • Short Ratio: 24.24
 

Frequently Asked Questions for TherapeuticsMD (NYSEMKT:TXMD)

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NYSEMKT:TXMD) issued its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.02. The company earned $5.50 million during the quarter, compared to analyst estimates of $5.76 million. TherapeuticsMD had a negative net margin of 462.94% and a negative return on equity of 77.41%. The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.11) EPS. View TherapeuticsMD's Earnings History.

Where is TherapeuticsMD's stock going? Where will TherapeuticsMD's stock price be in 2017?

6 brokerages have issued 12 month price targets for TherapeuticsMD's stock. Their predictions range from $10.50 to $33.00. On average, they expect TherapeuticsMD's share price to reach $21.08 in the next year. View Analyst Ratings for TherapeuticsMD.

What are analysts saying about TherapeuticsMD stock?

Here are some recent quotes from research analysts about TherapeuticsMD stock:

  • 1. Jefferies Group LLC analysts commented, "TXMD and its expert speakers/consultants made convincing cases for TX-001 and '004 as differentiated and needed HRTs for VMS/VVA. With strong senior talent and sound marketing strategies, we believe '004 can take meaningful share (even without a clean label with no boxed safety warnings), while '001 can become the new standard of care, especially in the compounding pharmacy channel (with no competition). TXMD remains a top 2017 small-cap pick." (3/2/2017)
  • 2. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (2/25/2017)

Who are some of TherapeuticsMD's key competitors?

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:

  • Tommy G. Thompson J.D., Independent Chairman of the Board
  • John C. K. Milligan IV, President, Secretary, Director
  • Robert G. Finizio, Chief Executive Officer, Director
  • Daniel A. Cartwright, Chief Financial Officer, Treasurer
  • Mitchell L. Krassan, Executive Vice President, Chief Strategy Officer
  • Michael Donegan, Vice President - Finance
  • Brian Bernick M.D., Chief Clinical Officer, Director
  • Jules A. Musing, Director
  • J. Martin Carroll, Independent Director
  • Cooper C. Collins, Independent Director

How do I buy TherapeuticsMD stock?

Shares of TherapeuticsMD can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TherapeuticsMD stock can currently be purchased for approximately $6.01.


MarketBeat Community Rating for TherapeuticsMD (NYSEMKT TXMD)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  254
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for TherapeuticsMD (NYSEMKT:TXMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.08

Analysts' Ratings History for TherapeuticsMD (NYSEMKT:TXMD)
Show:
DateFirmActionRatingPrice TargetDetails
7/11/2017Oppenheimer Holdings, Inc.UpgradeMarket Perform -> OutperformView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$20.00View Rating Details
5/11/2017Cantor FitzgeraldReiterated RatingOverweight$33.00View Rating Details
3/2/2017Jefferies Group LLCReiterated RatingBuy$18.00View Rating Details
12/6/2016GuggenheimReiterated RatingPositiveView Rating Details
12/4/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$10.50View Rating Details
7/11/2016Noble FinancialReiterated RatingBuy$17.50View Rating Details
(Data available from 8/20/2015 forward)

Earnings

Earnings History for TherapeuticsMD (NYSEMKT:TXMD)
Earnings by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Earnings History by Quarter for TherapeuticsMD (NYSEMKT TXMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017Q416($0.12)($0.12)$5.91 million$4.49 millionViewListenView Earnings Details
11/3/2016Q316($0.11)($0.13)$5.76 million$5.50 millionViewN/AView Earnings Details
8/4/2016Q216($0.10)($0.11)$5.63 million$4.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.09)($0.11)$5.73 million$4.93 millionViewN/AView Earnings Details
2/25/2016Q415($0.10)($0.10)$5.33 million$5.63 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.11)$5.01 million$5.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.16)$4.65 million$4.80 millionViewListenView Earnings Details
5/5/2015($0.10)($0.13)ViewN/AView Earnings Details
3/10/2015Q414($0.09)($0.10)$2.86 million$4.26 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.08)($0.12)ViewN/AView Earnings Details
5/6/2014Q1 14($0.06)($0.06)$3.08 million$2.80 millionViewN/AView Earnings Details
3/3/2014Q213($0.06)($0.06)$2.72 million$2.90 millionViewN/AView Earnings Details
5/8/2013Q113($0.06)($0.06)$1.32 million$1.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TherapeuticsMD (NYSEMKT:TXMD)
Current Year EPS Consensus Estimate: $-0.42 EPS
Next Year EPS Consensus Estimate: $-0.26 EPS

Dividends

Dividend History for TherapeuticsMD (NYSEMKT:TXMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TherapeuticsMD (NYSEMKT:TXMD)
Insider Trades by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Institutional Ownership by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Insider Trades by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/11/2016Cooper C CollinsDirectorBuy16,000$6.23$99,680.00View SEC Filing  
8/25/2015Angus C RussellDirectorBuy13,500$5.98$80,730.00View SEC Filing  
6/8/2015Mitchell KrassanEVPSell30,000$8.18$245,400.00View SEC Filing  
5/12/2015Angus C RussellDirectorBuy35,000$6.15$215,250.00View SEC Filing  
5/11/2015Tommy G ThompsonChairmanBuy6,000$6.09$36,540.00View SEC Filing  
5/8/2015J Martin CarrollDirectorBuy10,000$6.11$61,100.00View SEC Filing  
11/21/2014Daniel A CartwrightCFOSell40,000$3.91$156,400.00View SEC Filing  
9/4/2014Tommy G ThompsonDirectorBuy1,757$5.44$9,558.08View SEC Filing  
6/5/2014Cooper C CollinsDirectorBuy20,000$3.84$76,800.00View SEC Filing  
5/9/2014Robert Lapenta, Jr.DirectorBuy5,000$3.66$18,300.00View SEC Filing  
5/8/2014Tommy ThompsonDirectorBuy14,000$3.57$49,980.00View SEC Filing  
3/26/2014Brian BernickDirectorSell421,268$6.70$2,822,495.60View SEC Filing  
3/26/2014John C.K. Iv MilliganInsiderSell353,412$6.70$2,367,860.40View SEC Filing  
3/26/2014Robert FinizioCEOSell982,053$6.70$6,579,755.10View SEC Filing  
3/10/2014Mitchell KrassanEVPSell7,500$7.73$57,975.00View SEC Filing  
2/26/2014John C.K. Iv MilliganPresidentSell25,000$6.31$157,750.00View SEC Filing  
2/21/2014Robert FinizioCEOSell50,000$6.17$308,500.00View SEC Filing  
2/12/2014Brian BernickDirectorSell31,250$6.16$192,500.00View SEC Filing  
1/30/2014John C.K. Iv MilliganInsiderSell25,000$6.16$154,000.00View SEC Filing  
1/23/2014Robert G FinizioCEOSell50,000$5.70$285,000.00View SEC Filing  
1/13/2014Mitchell KrassanEVPSell7,500$5.73$42,975.00View SEC Filing  
1/8/2014Brian BernickDirectorSell31,250$5.13$160,312.50View SEC Filing  
8/26/2013Brian BernickInsiderSell1,600,000$1.55$2,480,000.00View SEC Filing  
8/26/2013Jules A MusingDirectorBuy5,282$2.15$11,356.30View SEC Filing  
6/14/2013Cooper C CollinsDirectorSell2,631,579$1.75$4,605,263.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for TherapeuticsMD (NYSEMKT:TXMD)
Latest Headlines for TherapeuticsMD (NYSEMKT:TXMD)
Source:
DateHeadline
nasdaq.com logoTherapeuticsMD (TXMD) Catches Eye: Stock Moves 5.9% Higher - Nasdaq
www.nasdaq.com - August 20 at 1:23 PM
finance.yahoo.com logoTherapeuticsMD (TXMD) Catches Eye: Stock Moves 5.9% Higher - Yahoo Finance
finance.yahoo.com - August 19 at 8:33 AM
zacks.com logoTherapeuticsMD (TXMD) Catches Eye: Stock Moves 5.9% Higher
www.zacks.com - August 18 at 8:13 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: TherapeuticsMD Inc. and Horizon Pharma
finance.yahoo.com - August 18 at 8:13 AM
streetinsider.com logoTherapeuticsMD (TXMD) Reports Publication of Manuscript on Women's Health Initiative Observational Study of ... - StreetInsider.com
www.streetinsider.com - August 17 at 8:46 AM
finance.yahoo.com logoTherapeuticsMD Announces Publication of Manuscript on the Women’s Health Initiative Observational Study of Vaginal Estrogen Use in Postmenopausal Women
finance.yahoo.com - August 17 at 8:45 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about TherapeuticsMD Inc.
finance.yahoo.com - August 14 at 8:01 AM
streetinsider.com logoTherapeuticsMD (TXMD) Issue Update on TX-004HR, Says FDA ... - StreetInsider.com
www.streetinsider.com - August 11 at 9:04 AM
streetinsider.com logoTherapeuticsMD (TXMD) Issue Update on TX-004HR, Says FDA Requested Additional Info on or Before Sept. 18, Tentative Meeting Set for Nov. 3
www.streetinsider.com - August 11 at 9:04 AM
finance.yahoo.com logoIHS Markit Score Update: Drop in demand for ETFs holding TherapeuticsMD Inc is a negative sign for its shares
finance.yahoo.com - August 10 at 9:04 AM
finance.yahoo.com logoEdited Transcript of TXMD earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 5 at 8:02 AM
finance.yahoo.com logoInvestor Network: TherapeuticsMD, Inc. to Host Earnings Call
finance.yahoo.com - August 4 at 9:27 AM
finance.yahoo.com logoTherapeuticsMD Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 9:27 AM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 29 at 8:39 AM
finance.yahoo.com logoETFs with exposure to TherapeuticsMD, Inc. : July 25, 2017
finance.yahoo.com - July 26 at 9:20 AM
finance.yahoo.com logoTherapeuticsMD to Host Second Quarter Financial Results Conference Call and Webcast on August 3
finance.yahoo.com - July 21 at 8:12 AM
prnewswire.com logoTechnical Reports on Drug Makers Equities -- TherapeuticsMD, GlaxoSmithKline, Novartis, and Impax Labs
www.prnewswire.com - July 20 at 9:13 AM
finance.yahoo.com logoCantor Remains Bullish on TherapeuticsMD Inc (TXMD) as Investors Await Clarity on TX-004
finance.yahoo.com - July 18 at 9:23 AM
benzinga.com logo20 Stocks Moving In Monday's Pre-Market Session - Benzinga
www.benzinga.com - July 17 at 9:14 AM
streetinsider.com logoTherapeuticsMD (TXMD) Announces Regulatory Update Regarding NDA for TX-004HR - StreetInsider.com
www.streetinsider.com - July 17 at 9:14 AM
finance.yahoo.com logoETFs with exposure to TherapeuticsMD, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 9:31 PM
finance.yahoo.com logoWhy TherapeuticsMD Inc Is Soaring Today
finance.yahoo.com - July 12 at 8:31 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: TherapeuticsMD, Inc. and Moleculin Biotech, Inc.
finance.yahoo.com - July 12 at 8:31 AM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Raised to "Outperform" at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 11 at 1:46 PM
nasdaq.com logoBurns J W & Co Inc Buys Amgen Inc, SPDR S&P Dividend, Vanguard REIT ETF - DNQ, Sells ...
www.nasdaq.com - July 8 at 3:01 PM
finance.yahoo.com logoTherapeuticsMD, Inc. breached its 50 day moving average in a Bearish Manner : TXMD-US : July 7, 2017
finance.yahoo.com - July 8 at 3:01 PM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 4 at 8:16 AM
finance.yahoo.com logoTherapeuticsMD, Inc. – Value Analysis (NYSE MKT:TXMD) : June 20, 2017
finance.yahoo.com - June 21 at 6:21 AM
finance.yahoo.com logoFINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) & Lead Plaintiff Deadline - June 19, 2017
finance.yahoo.com - June 20 at 8:48 AM
finance.yahoo.com logoDEADLINE TODAY: TXMD SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017
finance.yahoo.com - June 20 at 8:48 AM
finance.yahoo.com logoDEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 20 at 8:48 AM
finance.yahoo.com logoTherapeuticsMD, Inc. breached its 50 day moving average in a Bullish Manner : TXMD-US : June 19, 2017
finance.yahoo.com - June 19 at 8:43 AM
prnewswire.com logoStocks Under Scanner in the Drug Makers Space -- TherapeuticsMD ...
www.prnewswire.com - June 17 at 6:55 AM
prnewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ... - PR Newswire (press release)
www.prnewswire.com - June 17 at 6:55 AM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) & Lead Plaintiff Deadline - June 19, 2017
finance.yahoo.com - June 17 at 6:55 AM
finance.yahoo.com logoDEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017 -- TXMD
finance.yahoo.com - June 17 at 6:55 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TherapeuticsMD, Inc. of Class Action Lawsuit and Upcoming Deadline - TXMD
finance.yahoo.com - June 17 at 6:55 AM
finance.yahoo.com logoJUNE 19 DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 17 at 6:55 AM
finance.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) & Lead Plaintiff Deadline - June 19, 2017
finance.yahoo.com - June 15 at 2:54 AM
finance.yahoo.com logo5-DAY DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 15 at 2:54 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and Lead Plaintiff Deadline of June 19, 2017 -- TXMD
finance.yahoo.com - June 14 at 12:43 AM
finance.yahoo.com logoUPCOMING DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 14 at 12:43 AM
finance.yahoo.com logoINVESTOR ALERT - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) & Lead Plaintiff Deadline - June 19, 2017
finance.yahoo.com - June 12 at 7:50 PM
finance.yahoo.com logo7-DAY DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 12 at 7:50 PM
finance.yahoo.com logoINVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) & Lead Plaintiff Deadline - June 19, 2017
finance.yahoo.com - June 10 at 12:53 AM
finance.yahoo.com logoJune 19 Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against TherapeuticsMD, Inc.
finance.yahoo.com - June 10 at 12:53 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and Lead Plaintiff Deadline of June 19, 2017 -- TXMD
finance.yahoo.com - June 10 at 12:53 AM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 10 at 12:53 AM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 9 at 7:42 AM
finance.yahoo.com logoThe Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of TherapeuticsMD, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2017
finance.yahoo.com - June 9 at 1:41 AM

Social

This page was last updated on 8/20/2017 by MarketBeat.com Staff